Skip to main content

Table 2 Correlation between presence of at least one anti-angiogenesis-related adverse event and antitumor efficacy of apatinib

From: Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study

Clinical outcomes

With adverse events (n = 150)

Without adverse events (n = 119)

Unadjusted analysis

Multi-adjusted analysisa

HR/ORb (95% CI)

P valuec

HR/OR (95% CI)

P valued

Median overall survival (IQR), days

169 (96–255)

103 (58–201)

0.67 (0.51,0.88)

0.0039

0.64 (0.48,0.84)

0.001

Median progression-free survival (IQR), days

86.5 (57–150)

62 (41–121)

0.75 (0.58,0.98)

0.0309

0.79 (0.53,0.91)

0.007

Disease control rate, n (%)

39 (32.77)

82 (54.67)

2.47 (1.46,4.21)

< 0.001

2.67 (1.59,4.47)

< 0.001

Objective response rate, n (%)

6 (5.04)

11 (7.33)

1.49 (0.49.5.06)

0.443

1.42 (0.50,4.01)

0.505

  1. Adverse events are defined as hypertension, proteinuria, or hand and foot syndrome in the first 4 weeks of treatment
  2. HR hazard ratio, OR odds ratio, IQR interquartile range
  3. aAdjusted for sex, every 10-year increase in age, number of metastatic sites and ECOG PS
  4. bHR for overall survival and progression survival; OR for disease control rate and objective response rate
  5. c P values calculated from log-rank test for overall survival and progression survival, and chi-square test for disease control rate and objective response rate
  6. d P values calculated from Cox regression for overall survival and progression survival, and logistic regression for disease control rate and objective response rate